Alphatec Holdings, Inc. (NASDAQ:ATEC) EVP Craig E. Hunsaker Sells 50,000 Shares

Key Points

• Alphatec Holdings EVP Craig E. Hunsaker sold 50,000 shares of company stock for a total of $750,000.00, resulting in a 3.45% reduction in his ownership.
• The company's stock recently traded down 2.0% to $14.90, with a 12-month trading range between $4.88 and $15.46.
• Alphatec reported a quarterly earnings per share of $0.02, beating analyst expectations and showing a 27.5% year-over-year revenue increase.

Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report) EVP Craig E. Hunsaker sold 50,000 shares of Alphatec stock in a transaction dated Tuesday, August 5th. The stock was sold at an average price of $15.00, for a total value of $750,000.00. Following the sale, the executive vice president owned 1,400,018 shares of the company's stock, valued at approximately $21,000,270. This represents a 3.45% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Alphatec Trading Up 2.7%

Shares of NASDAQ:ATEC traded up $0.41 during trading on Monday, reaching $15.38. 236,346 shares of the stock were exchanged, compared to its average volume of 2,061,828. The company has a debt-to-equity ratio of 23.22, a quick ratio of 1.77 and a current ratio of 2.88. Alphatec Holdings, Inc. has a 12-month low of $4.88 and a 12-month high of $15.46. The firm has a market cap of $2.28 billion, a price-to-earnings ratio of -13.61 and a beta of 1.05. The firm's 50-day moving average price is $11.63 and its 200 day moving average price is $11.28.

Alphatec (NASDAQ:ATEC - Get Free Report) last issued its earnings results on Thursday, July 31st. The medical technology company reported $0.02 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.06) by $0.08. The business had revenue of $185.54 million during the quarter, compared to analysts' expectations of $178.85 million. Alphatec had a negative return on equity of 1,657.19% and a negative net margin of 24.33%. The company's revenue for the quarter was up 27.5% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.29) EPS. On average, sell-side analysts anticipate that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current fiscal year.

Institutional Trading of Alphatec

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Lido Advisors LLC raised its position in shares of Alphatec by 8.4% in the 4th quarter. Lido Advisors LLC now owns 12,247 shares of the medical technology company's stock valued at $112,000 after purchasing an additional 953 shares in the last quarter. Nisa Investment Advisors LLC raised its position in shares of Alphatec by 22.4% in the 2nd quarter. Nisa Investment Advisors LLC now owns 5,714 shares of the medical technology company's stock valued at $63,000 after purchasing an additional 1,045 shares in the last quarter. Oppenheimer Asset Management Inc. raised its position in shares of Alphatec by 8.4% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 14,244 shares of the medical technology company's stock valued at $158,000 after purchasing an additional 1,100 shares in the last quarter. Comerica Bank raised its position in shares of Alphatec by 66.8% in the 4th quarter. Comerica Bank now owns 3,116 shares of the medical technology company's stock valued at $29,000 after purchasing an additional 1,248 shares in the last quarter. Finally, ProShare Advisors LLC raised its position in shares of Alphatec by 5.6% in the 2nd quarter. ProShare Advisors LLC now owns 23,790 shares of the medical technology company's stock valued at $264,000 after purchasing an additional 1,254 shares in the last quarter. 66.35% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms have commented on ATEC. Wall Street Zen upgraded Alphatec from a "hold" rating to a "buy" rating in a report on Saturday. Lake Street Capital raised shares of Alphatec to a "buy" rating and set a $18.00 price objective for the company in a research note on Monday, June 16th. HC Wainwright reaffirmed a "buy" rating and set a $20.00 price objective on shares of Alphatec in a research note on Monday, April 14th. Barclays reaffirmed an "overweight" rating and set a $22.00 price objective (up previously from $21.00) on shares of Alphatec in a research note on Monday, August 4th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $16.00 price objective on shares of Alphatec in a research note on Friday, May 2nd. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $18.50.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.